Medplex Biotech

Medplex Biotech is a San Diego-based biopharmaceutical company focused on developing innovative small molecule drugs for oncology. The company specializes in targeting the ubiquitin-proteasome system, with a particular emphasis on deubiquitinating enzymes (DUBs) to address unmet needs in DNA damage response (DDR) pathways. Its lead candidate, MPX-022, is a highly selective USP1 inhibitor currently in IND-enabling studies for the treatment of BRCA-deficient solid tumors. By leveraging synthetic lethality, Medplex aims to develop therapies that can be used as monotherapy or in combination with PARP inhibitors to overcome drug resistance. The company is led by experienced drug discovery professionals and utilizes a proprietary platform to identify novel targets within the ubiquitin system.